证券之星消息，8月12日水泥板块较上一交易日下跌1.85%，天山股份领跌。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。水泥板块个股涨跌见下表： 从资金流向上来看，当日水泥板块主力资金净流出10.47亿元，游资资金净流出6442.66万元，散户资金净 流入11.12亿元。水泥板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000672 上峰水泥 | | = 191.19万 | 1.81% | -621.94万 | -5.88% | 430.75万 | 4.07% | | 002671 龙泉股份 | | -108.92万 | -2.10% | 139.51万 | 2.69% | -30.59万 | -0.59% | | 605122 四方新材 | | -360.78万 | -6.26% | 111.49万 | 1.93% | 249.29万 ...

证券简称：尖峰集团 证券代码：600668 编号：临 2025-037 浙江尖峰集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 回购方案首次披露日 | 2025年4月22日 | | --- | --- | | 回购方案实施期限 | 自董事会审议通过本次回购股份方案之日起12个月内 | | 预计回购金额 | 2,000万元-4,000万元 | | 回购用途 | □减少注册资本 | | | √用于员工持股计划或股权激励 | | | □用于转换公司发行的可转换为股票的公司债券 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 0股 | | 累计已回购股数占总股本比例 | 0.00% | | 累计已回购金额 | 0.00元 | | 实际回购价格区间 / | | 重要内容提示： 一、回购股份的基本情况 浙江尖峰集团股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开 了第十二届董事会第 7 次会议，审议通过了《关于以集中竞价交易 ...

Group 1: Company Performance - Ningde Times reported a net profit of 30.5 billion yuan for the first half of the year, representing a year-on-year increase of 33.02% [1] - The company achieved revenue of 178.9 billion yuan, an increase of 7.27% compared to the same period last year [1] - Gross profit reached 44.8 billion yuan, up 14.45% year-on-year, with a gross margin of 25.02%, an increase of 1.57 percentage points from the previous year [1] Group 2: Stock Trading and Suspensions - Shangwei New Materials announced a suspension of trading due to multiple instances of abnormal stock price fluctuations, with the suspension expected to last no more than three trading days [2] - Jinchengzi is planning to acquire 55% of Samit Optoelectronics, leading to a stock suspension for up to ten trading days [3] - Sanchao New Materials is also planning a change in control, resulting in a stock suspension for up to two trading days [6] - Hehua Co. announced a stock suspension due to potential changes in its controlling shareholder [9] Group 3: Major Investments and Projects - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project [5] - The company will use its own funds for this investment, with the final amount to be confirmed based on state-approved preliminary design estimates [5] Group 4: Other Corporate Actions - Sunshine Dairy's controlling shareholder sold a total of 1.1452 million shares, accounting for 0.41% of the company's total share capital, without triggering any significant changes in control [4] - Nanjing Pharmaceutical is in the process of planning the acquisition of a domestic pharmaceutical technology asset group, with uncertainty regarding whether it constitutes a major asset restructuring [7]

公告显示，磷酸特地唑胺(Tedizolid phosphate)，又称磷酸泰地唑胺、特地唑胺磷酸酯、泰地唑胺磷酸 酯，是由CubistPharmaceuticals公司研发的新型抗细菌感染用药，为特地唑胺的前体，可经口服或静脉 注射后通过磷酸酯酶转化成特地唑胺。特地唑胺是第二代恶唑烷酮类抗生素，是一种蛋白质合成抑制 剂，通过与细菌核糖体50S亚基结合，抑制细菌蛋白质的合成，发挥抗菌作用，与其它类别的抗生素之 间不易产生交叉耐药。 本报讯(记者邬霁霞见习记者王楠)7月30日晚间，浙江尖峰集团（600668）股份有限公司发布公告称， 其子公司安徽尖峰北卡药业有限公司(以下简称"尖峰北卡")收到国家药品监督管理局关于化学原料药磷 酸特地唑胺的《化学原料药上市申请批准通知书》。 截至公告发布当日，磷酸特地唑胺原料药项目累计研发投入约1026.94万元，尖峰北卡已完成相关生产 线建设。此次原料药获批，标志着该产品已达到国家原料药审评技术标准，可在国内销售，有助于增强 尖峰北卡的市场竞争力。 ...

Core Viewpoint - The announcement indicates that Jianfeng Group's subsidiary, Anhui Jianfeng Beika Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Phosphoric Acid Tedizolid [1] Group 1 - Jianfeng Beika has established the necessary production line for Phosphoric Acid Tedizolid, which signifies its readiness to manufacture the drug [1] - The approval confirms that the raw material drug meets the national technical standards for raw material drug review, allowing it to be sold in the domestic market [1] - This development is expected to help expand the business scope of the subsidiary [1]

证券代码：600668 证券简称：尖峰集团 编号：临 2025-036 浙江尖峰集团股份有限公司 关于子公司获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 风险提示：由于医药产品具有高科技、高风险、高附加值的特点，不仅 药品的前期研发及研制、报批到投产的周期长、投入大、环节多，而且药品的生 产和销售也容易受到国家政策、市场环境变化等因素影响，具有较大不确定性。 敬请广大投资者注意投资风险。 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的下属子公司安徽 尖峰北卡药业有限公司（以下简称"尖峰北卡"）收到国家药品监督管理局关于化 学原料药磷酸特地唑胺的《化学原料药上市申请批准通知书》（通知书编号： 2025YS00633），现将相关情况公告如下： 一、化学原料药的基本情况 化学原料药名称：磷酸特地唑胺 包装规格：5kg/桶、10kg/桶、20kg/桶 通知书编号：2025YS00633 化学原料药注册标准编号：YBY67532025 生产企业名称：安徽尖峰北卡药业有限公司 生产企 ...

Core Viewpoint - The company has received approval for the chemical raw material drug Phosphoric Acid Tezolamide, indicating compliance with national standards and enabling market sales, which will help expand the subsidiary's business scope [1] Group 1 - The subsidiary Anhui Jianfeng Beika Pharmaceutical Co., Ltd. has obtained the "Approval Notice for the Listing Application of Chemical Raw Materials" from the National Medical Products Administration [1] - The approval signifies that the raw material drug meets the relevant technical standards for chemical raw materials review in the country [1] - The establishment of the corresponding production line at the subsidiary supports the capability to produce and sell the approved drug in the domestic market [1]

格隆汇7月30日丨尖峰集团(600668.SH)公布，下属子公司安徽尖峰北卡药业有限公司收到国家药品监督 管理局关于化学原料药磷酸特地唑胺的《化学原料药上市申请批准通知书》。磷酸特地唑胺 (Tedizolidphosphate)，又名磷酸泰地唑胺、特地唑胺磷酸酯、泰地唑胺磷酸酯。磷酸特地唑胺是由 CubistPharmaceuticals公司研发的新型抗细菌感染用药。 ...

Core Viewpoint - The announcement indicates that Jianfeng Group's subsidiary, Anhui Jianfeng Beika Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Fosfomycin Trometamol, which is a new antibacterial medication developed by Cubist Pharmaceuticals [1] Company Summary - Jianfeng Group's subsidiary has established production lines capable of manufacturing Fosfomycin Trometamol, indicating readiness to enter the market [1] - The approval signifies that the raw material drug meets the national technical standards for raw material drug review, allowing it to be sold in the domestic market [1] - This development is expected to help expand the business scope of the subsidiary [1]

Group 1 - The core point of the article is that Jianfeng Group (600668) announced the approval of its subsidiary Jianfeng Beika's application for the chemical raw material drug Phosphate Tedizolid by the National Medical Products Administration [1] - Phosphate Tedizolid is a new antibacterial drug developed by Cubist Pharmaceuticals [1]